FDA approves marketing for new Alzheimer's early detection test
May 06, 2022 at 13:44 PM EDT
The Lumipulse G β-Amyloid Ratio (1-42/1-40) test is available at clinical laboratories nationwide for adult patients aged 55 years and older who are presenting with cognitive impairment and being evaluated for Alzheimer’s disease and other causes of cognitive decline.
